On May 27, 2022, Fudan-Zhangjiang issued an announcement stating that the company intends to cooperate with WD Pharma on WD-1603 and sign related agreements. The subject of this cooperation is a product for the treatment of Parkinson's disease being developed by WD Pharma, which is a product using a proprietary technology, with controlled-release components for the treatment of Parkinson's disease, which is currently at Phase II clinical trials. The Company will conduct Phase III clinical trials based on the completion of Phase II clinical trials and the achievement of expected results by WD Pharma. The Company will become the Marketing Authorization Holder (MAH) for the product in Mainland China and will be responsible for manufacturing